switching from semiglutide to tirzepatide and Semaglutide key differences, weight loss results (2026) Switching from semaglutide to tirzepatide

maintenance phase is the heavy draw 26 weeks 13 vials Standard Phase 2 duration 32 weeks 16 vials Phase 2 T2D study duration 68 weeks 30 vials REDEFINE 1 / REDEFINE 2 endpoint duration Peptide Vials (10 mg vial, 2.4 mg/week target) Each 10 mg vial covers about 4 weekly doses at 2.4 mg/week

Tirzepatide (Mounjaro, Zepbound): Tirzepatide is a type of medication called a GLP-1/GIP receptor agonist

CJC-1295 No DAC with Ipamorelin: Chemical Identity CJC-1295 No DAC with Ipamorelin is a synthetic peptide combination consisting of a 29-amino-acid growth hormone-releasing hormone analog and a five-amino-acid ghrelin receptor agonist

They look at medical history and possible risks

This makes true microdosing (starting below 2.5 mg) impossible with brand-name products

Ipamorelin avoids this entirely, even at very high doses